Live Breaking News & Updates on Tipapkinogen Sovacivec Therapeutic

Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers
-
Trial will focus on patients without liver metastases, based on encouraging data in Phase Ib/II study
-
Trial targets indications where clinical outcomes can be improved versus standard therapeutic options and immune checkpoint inhibitors ( ICIs )
-
Continued clinical collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to conduct the expanded Phase II study
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the expansion of a randomized, controlled study with TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital tumors (NCT: 03260023) ....

Distrito Federal , United States , United Kingdom , Lucie Larguier , Christophe Le Tourneau , Le Tourneau , Transgene Euronext , Sylvie Berrebi , Maud Brandely , Citigate Dewe Rogerson , Head Of The Department Drug Development , Information Center Statistics , Curie Institute , Merck Kga , Pfizer Inc , Merck Kgaa , Corporate Communications , Information Center Prevention , American Cancer Society , Euronext Paris , Drug Development , Principal Investigator , Chief Medical Officer , Positive Cancers , Artificial Intelligence , Approved Indications ,